Akero Therapeutics Inc.

NASDAQ: AKRO · Real-Time Price · USD
49.17
-0.92 (-1.84%)
At close: Aug 15, 2025, 3:04 PM

Akero Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
4K 4K 4K 284K 284K 284K 284K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
3K 4K 5K 5K 9K 77K 144K 207K 268K 264K 260K 258K 252K 247K 244K 181K 121K 61K
Gross Profit
1K n/a -1K -5K -9K -77K -144K -207K -268K -264K -260K -258K -252K -247K -244K -181K -121K -61K
Operating Income
-321.48M -306.35M -285.42M -269.27M -234.18M -204.07M -172.87M -136.42M -125.89M -117.86M -115.16M -122.17M -110.44M -111.81M -100.89M -98.23M -95.42M -82.9M
Interest Income
42.3M 41.74M 38.03M 36.41M 34.01M 28.43M 24.21M 16.63M 8.78M 3.62M 266K 266K 266K 22K 38K 38K 173K 420K
Pretax Income
-283.96M -269.44M -252.06M -237.22M -204.18M -179.27M -151.76M -119.63M -115.52M -111.83M -112.03M -121.4M -110.19M -111.72M -100.78M -98.06M -95.14M -82.41M
Net Income
-283.96M -269.44M -252.06M -237.22M -204.18M -179.27M -149.29M -114.59M -109.93M -106.25M -108.89M -120.83M -110.16M -111.69M -100.78M -98.06M -95.14M -82.41M
Selling & General & Admin
41.14M 39.94M 37.92M 37.67M 36.18M 33.41M 31.07M 29.69M 32.71M 31.3M 29.87M 27.5M 21.38M 20.14M 19.13M 18.47M 17.75M 16.18M
Research & Development
280.35M 266.41M 247.5M 231.6M 198M 170.66M 141.8M 106.73M 93.18M 86.56M 85.28M 94.67M 89.06M 91.67M 81.76M 79.76M 77.67M 66.73M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a 244K 244K 259K 282K 71K 109K 166K 278K 245K
Operating Expenses
321.48M 306.35M 285.42M 269.27M 234.18M 204.07M 172.87M 136.42M 125.89M 117.86M 115.16M 122.17M 110.44M 111.81M 100.89M 98.23M 95.42M 82.9M
Interest Expense
2.46M 2.52M 4.67M 4.37M 4.01M 3.63M 3.1M 2.56M 2M 1.2M 739K 377K 53K n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a -1K -2K -4K -4K -3K -2K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
321.49M 306.36M 285.43M 269.27M 234.18M 204.07M 172.87M 136.42M 125.89M 117.86M 115.16M 122.17M 110.44M 111.81M 100.89M 98.23M 95.42M 82.9M
Income Tax Expense
n/a n/a -42.28K -42.28K -42.28K -42.28K -2.46M -5.04M -5.59M -5.59M -3.15M -582K -84K -134K -162K -162K -117K -67K
Shares Outstanding (Basic)
81.72M 78.66M 70.57M 69.44M 69.16M 59.31M 55.72M 55.61M 51.87M 46.94M 46.76M 38.66M 35.38M 35.01M 34.89M 34.86M 34.81M 34.74M
Shares Outstanding (Diluted)
81.72M 78.66M 70.57M 69.44M 69.16M 59.31M 55.72M 55.61M 51.87M 46.94M 46.76M 38.66M 35.38M 35.01M 34.89M 34.86M 34.81M 34.74M
EPS (Basic)
-3.8 -3.75 -3.75 -3.75 -3.41 -3.2 -2.8 -2.25 -2.45 -2.62 -2.86 -3.35 -3.14 -3.2 -2.89 -2.82 -2.75 -2.49
EPS (Diluted)
-3.8 -3.75 -3.75 -3.75 -3.41 -3.2 -2.8 -2.25 -2.45 -2.62 -2.86 -3.35 -3.14 -3.2 -2.89 -2.82 -2.75 -2.49
EBITDA
-279.17M -264.59M -247.37M -232.85M -200.16M -175.56M -148.52M -116.86M -113.25M -110.38M -111.03M -120.83M -109.95M -111.54M -100.69M -98.03M -95.3M -82.88M
EBIT
-279.19M -264.61M -247.39M -232.86M -200.17M -175.64M -148.66M -117.07M -113.52M -110.64M -111.29M -121.04M -110.15M -111.73M -100.83M -98.17M -95.38M -82.9M
Depreciation & Amortization
20.5K 21.5K 18K 5K 9K 77K 144K 207K 268K 264K 260K 258K 252K 247K 244K 192K 138K 1.4M